Care of Women with HIV Who Are Substance Users

Care of Women with HIV Who Are Substance Users

Introduction and Gender Differences

Substance Use Guidelines Committee, February 2009

Clinicians need to be cognizant of the differences in patterns of substance use in women as opposed to men in order to develop the most effective management strategies for them. Clinicians should also be aware of treatment needs that may be specific to women experiencing substance use disorders. This chapter addresses gender differences in the causes, progression, and effective methods of treatment for substance use disorders among women.

Prevalence

The 2007 National Survey on Drug Use and Health (NSDUH, formerly the NHSDA) found that rates of lifetime, past-year, and past-month illicit drug use were higher for males than females among persons aged 12 or older (51% vs 42%, 18% vs 12%, 11% vs 6%, respectively). In addition, 13% of males met criteria for any illicit drug or alcohol abuse or dependence in the past year compared with 6% of females. However, gender differences were absent among adolescents (aged 12-17): rates of substance dependence or abuse in the past year were 8.0% for both males and females [SAMHSA 2008].

In 2007, use of marijuana during the past month was twice as high for males than for females. However, females had similar rates as males of past-month use of tranquilizers, stimulants, methamphetamine, sedatives, and OxyContin® [SAMHSA 2008].

KEY POINT
  • Women are more likely to misuse prescription drugs than men.

Data from the NSDUH found that from 2006 to 2007, there was no change among males for the rate of past-month nonmedical use of psychotherapeutic medications but there was a slight decrease among females (2.5% to 2.3%) [SAMHSA 2008]. However, an overview of literature from 1966 to 2000 found that although the incidence of alcohol abuse or dependence is greater among men than among women, women with alcohol abuse or dependence are more likely to seek medical help, but are less likely to be identified by their clinicians as having a problem [Brienza and Stein 2002].

The use of crack cocaine has been associated with high-risk behaviors and has disproportionately affected African American women [Wechsberg et al. 2004]. Studies have shown that smoking crack cocaine and exchanging sex for money are co-factors for the risk of HIV infection, especially for women [Logan and Leukefeld 2000]. Women who smoke crack are more likely than non-crack-using women to 1) sell sex, 2) have more sexual partners, and 3) have a sexually transmitted infection (STI) [Logan and Leukefeld 2000]. Women who use crack are also more likely to be assaulted during a sex exchange [Logan et al. 2003].

A study of HIV-infected female crack cocaine users found that 72% of these women reported a recent 3- to 4-day crack binge, during which they had sex with an average of 3.1 partners. Binge users were less likely to use condoms and more likely to report trading sex for money or drugs [Harzke 2009].

Patterns and Impact of Use

Although fewer than 30% of new AIDS cases among women are due to injection drug use, 60% of new AIDS cases in women are classified as drug-related due to women sexually acquiring HIV from drug-using partners.

KEY POINT
  • Female injection drug users (IDUs) are more likely than male IDUs to adopt the drug use patterns of their partners and to share needles with their partners [Najavits 2002; Gordon 2001].

Clinicians should counsel patients to practice risk-reduction activities including safer sexual activities, needle sharing, and other drug-using activities that have potential for exposure to blood and body fluids to prevent acquisition or transmission of HIV and other STDs (see NYSDOH AI Working With the Active User Guideline).

Although women often start using drugs and alcohol at older ages than men, some studies suggest that women may become addicted more quickly. Some studies suggest that women undergo a “telescoped course” from using to abusing alcohol [Brienza and Stein 2002; Randall et al. 1999; Brady and Randall 1999]. Alcohol-dependent women are at greater risk for developing alcoholic hepatitis and cirrhosis, when alcohol consumption and duration of drinking levels are considered [Becker et al. 1996]. Several factors, including lower body weight, lower total body water, and lower levels of alcohol dehydrogenase, may contribute to greater sensitivity to alcohol’s long-term sequellae among women than men.

References

Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study. Hepatology 1996;23:1025-1029.

Brady KT; Randall CL. Gender differences in substance use disorders. Psychiatr Clin North Am 1999;22:241-252.

Brienza RS, Stein MD. Alcohol use disorders in primary care: Do gender-specific differences exist? J Gen Intern Med 2002;17:387-397.

Gordon SM. Women and Addiction: Gender Issues in Abuse and Treatment. Wernersville, PA: Caron Foundation: 2001.

Harzke AJ, Williams ML, Bowen AM. Binge use of crack cocaine and sexual risk behaviors among African-American, HIV-positive users. AIDS Behav 2009;13(6):1106-18.

Logan TK, Cole J, Leukefeld C. Gender differences in the context of sex exchange among individuals with a history of crack use. AIDS Educ Prev 2003;15:448-464.

Logan TK, Leukefeld C. Sexual and drug use behaviors among female crack users: A multi-site sample. Drug Alcohol Depend 2000;58:237-245.

Najavits LM. Seeking Safety: A Treatment Manual for PTSD and Substance Abuse. New York: Guiford; 2002.

Randall CL, Roberts JS, Del Boca FK, et al. Telescoping of landmark events associated with drinking: A gender comparison. J Stud Alcohol 1999;60:252-260.

Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2007 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NSDUH Series H-34, DHHS Publication No. SMA 08-4343. Rockville, MD; 2008. 

Wechsberg WM, Lam WKK, Zule WA, et al. Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. Am J Public Health 2004;94:1168-1173.

Barriers to Treatment

Substance Use Guidelines Committee, February 2009

RECOMMENDATIONS
Barriers to Treatment
  • As part of a patient’s substance use history, the clinician should inquire about the addiction patterns of the patient’s partner(s) when obtaining a patient’s substance use history.
  • When referring substance-using women to drug treatment programs, clinicians should choose programs that are best able to meet the particular needs of the individual patient.

Women’s access to HIV-related care and substance use treatment is often hampered by a variety of barriers, including childcare and eldercare obligations. Such barriers should be considered in each woman’s evaluation and treatment. Pregnancy may pose additional barriers because some drug treatment facilities may not provide suitable support for women who are pregnant. Women with young children may have ongoing difficulty accessing outpatient day treatment programs and residential programs because of inadequate or non-existent childcare. For substance-using pregnant women, the possibility of HIV testing during pregnancy or incarceration for child abuse may generate or intensify fears, suspicion, and distrust of the healthcare system and treatment programs, thereby preventing them from seeking services. Fear of removal of children from the home by the welfare system, lack of financial resources, and lack of emotional support from substance-using partners are other obstacles to treatment that some substance-using women face.

See the NYSDOH AI Treatment Modalities Guideline for more guidance on choosing the most suitable program for the individual patient.

Contraception

Substance Use Guidelines Committee, February 2009

RECOMMENDATIONS
Contraception
  • Clinicians should counsel all HIV-infected women to use latex or polyurethane condoms, regardless of current contraceptive method of choice.
  • Clinicians should avoid the use of combined oral contraceptives in women with abnormal liver function.

Because combined oral contraceptives are metabolized by the liver, they should generally be avoided in women with abnormal liver function, which may be caused by alcohol abuse, acute or chronic viral hepatitis, or ARV therapy. Some drug users may prefer other forms of contraception, such as an IUD or injectable progestogens, which both reduce user dependency and menstrual flow.

Pregnancy

Substance Use Guidelines Committee, February 2009

RECOMMENDATIONS
Pregnancy and Substance Use
  • Clinicians should counsel both HIV-infected pregnant women and HIV-infected women of childbearing potential about the specific effects of alcohol and illicit drugs on the developing fetus.
  • Pregnant HIV-infected substance users should be co-managed by an experienced HIV provider and an obstetrical care provider experienced in the care of HIV-infected women.
  • Although there is no mandate in New York State to report substance use during pregnancy to child protective services, New York State law requires clinicians to report cases of suspected abuse or neglect involving other children in the household to the New York State Central Registry at 1-800-635-1522.
Opioid Use in Pregnancy
  • If a woman who is dependent on opioids becomes pregnant, the clinician should discuss treatment options with her, informing her that methadone maintenance is preferred to detoxification. If she is already enrolled in a methadone maintenance program, the clinician should advise her to continue it.
  • Clinicians should arrange a consultation between a pediatric HIV Specialist and the pregnant opioid user to discuss the possibility of neonatal withdrawal syndrome and the care of the neonate.
Alcohol Use in Pregnancy
  • Clinicians should recommend inpatient or outpatient treatment for alcohol-dependent pregnant women.
  • Pregnant women who are physically dependent on alcohol should undergo medically supervised detoxification prior to initiating longer-term abstinence-based treatment.
Cocaine Use in Pregnancy
  • Clinicians should recommend inpatient or outpatient treatment for cocaine-dependent pregnant women.

Many women who use drugs during pregnancy either do not disclose their substance-using behavior or avoid prenatal care and treatment because of stigmatization, fear of losing custody of their children, or fear of prosecution. Because of the possible physical adverse effects to the fetus, such use during pregnancy can provoke strong emotions in laypersons and clinicians alike. Clinicians should educate patients in a professional, nonjudgmental manner regarding the risks associated with each substance.

Clinicians can affect a patient’s drug use by screening, identifying, and counseling about drug use and the benefits of drug treatment (for a description of treatment modalities, see NYSDOH AI Treatment Modalities Guideline) . Studies have shown that brief interventions by clinicians can reduce the rates of hazardous drinking in pregnant women [Chang et al. 1999].

Currently, there is no mandate in New York State to report substance use during pregnancy to child protective services. However, if the clinician suspects that other children in the household are being abused or neglected, the clinician must report the case to the New York State Central Registry at 1-800-635-1522.

Opioid use: Methadone maintenance treatment is an effective therapy for opioid-dependency during pregnancy, and does not adversely affect fetal or post-natal development. Some women receiving methadone maintenance treatment are inappropriately urged to detoxify from methadone despite scientific evidence suggesting that opioid withdrawal may result in premature labor or spontaneous abortion. Thus, initiating or continuing methadone maintenance in pregnant women is a recommended and effective strategy for treating opioid-dependency.

The FDA considers pregnancy a contraindication for buprenorphine use; however, many clinicians feel that buprenorphine is a safer alternative to methadone or heroin use. The Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines suggest that since no adverse affects of buprenorphine on pregnancy have been observed in case series, its use may be considered in pregnancy on a case-by-case basis.

Alcohol use: Currently, there is no known exact dose-response relationship between the amount of alcohol consumed during the prenatal period and the extent of damage caused by alcohol in the infant; thus, a safe level of prenatal alcohol consumption has not been determined. The US Surgeon General and the Secretary of Health and Human Services recommend abstinence at conception and during pregnancy [Stratton et al. 1996]. Binge drinking has a greater negative effect on the unborn infant than consumption of low amounts of alcohol over several days.

KEY POINT
  • Infants whose mothers consume excessive amounts of alcohol during pregnancy are at high risk for adverse effects, such as fetal alcohol syndrome, regardless of the HIV infection status of the mother.

For more information on managing HIV-infected patients who use alcohol, see NYSDOH AI Alcohol Use and Abuse Guideline > Identifying Alcohol Abuse.

Cocaine use: Cocaine use reduces placental blood flow and may lead to intrauterine fetal growth restriction, premature labor, or placental abruption. Although many studies on the long-term effects of cocaine-exposed infants have not found a negative association with developmental test scores when other factors are adequately controlled for [Frank et al. 2001], use of cocaine should be discouraged during pregnancy and clinicians should refer cocaine-dependent pregnant women to in- or outpatient treatment.

References

Chang G, Wilkins-Haug L, Berman S, et al. Brief intervention for alcohol use in pregnancy: A randomized trial. Addiction 1999;94:1499-1508.

Frank DA, Augustyn M, Knight W, et al. Growth, development, and behavior in early childhood following prenatal cocaine exposure: A systematic review. JAMA 2001;285:1613-1625.

Stratton K, Howe C, Battaglia F (eds). Institute of Medicine Summary: Fetal Alcohol Syndrome. Washington, DC: National Academy Press, 1996.

Trauma

Substance Use Guidelines Committee, February 2009

RECOMMENDATION
Trauma
  • Clinicians should screen all substance-using women for trauma and physical and/or sexual abuse, which may trigger or exacerbate substance use in female patients. Initial assessments of new female patients should include questions that document whether a woman has a history of past or current physical or sexual abuse.

Numerous studies have found that women in substance use treatment are twice as likely as other women to report a history of childhood physical or sexual abuse; a similar association does not exist among men. Substance use and physical and/or sexual abuse seem to be bi-directional: a prior history of trauma (physical/sexual abuse or violence) may predispose a woman to drug and alcohol problems, while drug and alcohol use may predispose a woman to trauma [Messman-Moore et al. 2009]. Possible mediators of this association include resulting depression, anxiety, conduct disorders, and PTSD. Sexual abuse, untreated trauma, and the attendant stigma often result in reluctance or failure to seek medical care. 

Reference

Messman-Moore TL, Ward RM, Brown AL. Substance use and PTSD symptoms impact the likelihood of rape and revictimization in college women.J Interpers Violence 2009;24:499-521.

All Recommendations

Substance Use Guidelines Committee, February 2009

ALL RECOMMENDATIONS: MEDICAL CARE OF HIV-INFECTED SUBSTANCE-USING WOMEN
Barriers to Treatment
  • As part of a patient’s substance use history, the clinician should inquire about the addiction patterns of the patient’s partner(s) when obtaining a patient’s substance use history.
  • When referring substance-using women to drug treatment programs, clinicians should choose programs that are best able to meet the particular needs of the individual patient.
Contraception
  • Clinicians should counsel all HIV-infected women to use latex or polyurethane condoms, regardless of current contraceptive method of choice.
  • Clinicians should avoid the use of combined oral contraceptives in women with abnormal liver function.
Pregnancy and Substance Use
  • Clinicians should counsel both HIV-infected pregnant women and HIV-infected women of childbearing potential about the specific effects of alcohol and illicit drugs on the developing fetus.
  • Pregnant HIV-infected substance users should be co-managed by an experienced HIV provider and an obstetrical care provider experienced in the care of HIV-infected women.
  • Although there is no mandate in New York State to report substance use during pregnancy to child protective services, New York State law requires clinicians to report cases of suspected abuse or neglect involving other children in the household to the New York State Central Registry at 1-800-635-1522.
Opioid Use in Pregnancy
  • If a woman who is dependent on opioids becomes pregnant, the clinician should discuss treatment options with her, informing her that methadone maintenance is preferred to detoxification. If she is already enrolled in a methadone maintenance program, the clinician should advise her to continue it.
  • Clinicians should arrange a consultation between a pediatric HIV Specialist and the pregnant opioid user to discuss the possibility of neonatal withdrawal syndrome and the care of the neonate.
Alcohol Use in Pregnancy
  • Clinicians should recommend inpatient or outpatient treatment for alcohol-dependent pregnant women.
  • Pregnant women who are physically dependent on alcohol should undergo medically supervised detoxification prior to initiating longer-term abstinence-based treatment.
Cocaine Use in Pregnancy
  • Clinicians should recommend inpatient or outpatient treatment for cocaine-dependent pregnant women.
Trauma
  • Clinicians should screen all substance-using women for trauma and physical and/or sexual abuse, which may trigger or exacerbate substance use in female patients. Initial assessments of new female patients should include questions that document whether a woman has a history of past or current physical or sexual abuse.